Notice of the extraordinary general meeting of Cell Impact AB (publ)

Cell Impact AB has convened an extraordinary general meeting on 30 January 2026 to approve a package of recapitalization measures including a reduction of share capital by SEK 29,458,474.56 (lowering quota value from SEK 0.20 to SEK 0.10) and a rights issue to raise up to SEK 29,458,474.56 via a maximum of 294,584,745 new shares at SEK 0.13 per share (record date 4 Feb 2026; subscription period 6–20 Feb 2026). The board also proposes a conditional bonus issue of SEK 11,783,390 if the rights issue is not fully subscribed and authorization to issue shares and warrants to guarantors and a bridge-loan provider; several resolutions require a two‑thirds majority and are interdependent, making the package dilutive but aimed at recapitalizing the fuel-cell flow‑plate supplier.

Analysis

Market structure: The EGM and proposed 1:1 rights issue at SEK 0.13 would, if fully subscribed, double the share count from 294.6m to 589.2m — immediate owner dilution ≈50% and heavy downward pressure on market cap unless proceeds fund rapid commercial scale-up. Winners in this restructuring are guarantors and the bridge-lender (who get shares/warrants and priority economics); losers are opportunistic minority shareholders and any liquidity providers who don’t participate.

Risk assessment: Tail risks include a failed rights issue triggering a value-transfer bonus issue or heavier dilutive compensation to guarantors, or the bridge lender converting warrants to >10–20% equity causing de-facto control change. Key near-term dates are EGM 30 Jan 2026, record date 22 Jan, rights record date 4 Feb and subscription 6–20 Feb — failure to clear these windows is the highest short-term existential risk.

Trade implications: The mechanics create binary trades: (A) short/put exposure to Cell Impact into/through 20 Feb because dilution is almost certain unless market subscribes at a premium; (B) rotate into larger-cap, cash-rich fuel-cell suppliers (examples: NEL.OL, BLDP) where balance-sheet risk is lower. Use pair trades (long NEL/short CELL IMPACT) and option hedges around the subscription window to size uncertainty.

Contrarian angles: Consensus focuses on dilution but underweights patent/IP optionality — if management converts proceeds to one or two commercial contracts within 12–24 months, upside could be >2x from distressed levels. That’s conditional and hinges on transparent disclosure of guarantors, bridge terms and order-book milestones; absence of those disclosures is a structural value trap.

Key Decisions for Investors

• If you hold Cell Impact shares and can allocate fresh capital: subscribe pro-rata at SEK 0.13 during 6–20 Feb 2026 to avoid ~50% dilution (size = maintain current % ownership). Only do this if you have conviction of commercial revenue within 12 months; otherwise do not top-up.
• If you do not want to fund: sell shares before the record date (22 Jan 2026) or sell received subscription rights immediately; target execution at a price no lower than SEK 0.15 if liquidity allows, otherwise accept a -30% stop from current market price to limit downside exposure through the rights window.
• Establish a modest short (0.5–1% NAV) in Cell Impact into the EGM and subscription window; add puts expiring Mar–Jun 2026 sized to 0.5% NAV where available. Take profits or reassess after 20 Feb 2026 once subscription results are public.
• Pair trade: allocate 2–3% NAV long in larger, cash-strong fuel-cell/electrolyzer names (e.g., NEL.OL, BLDP) and size a 0.5–1% short in Cell Impact to express capital-quality dispersion. Rebalance after 21 Feb 2026 depending on subscription uptake and disclosure of guarantor/bridge conversion terms.
• Require three explicit disclosures within 14 days post-EGM before raising exposure: (1) identity and stake cap of guarantors, (2) bridge loan principal, interest and conversion/warrant strike, (3) use-of-proceeds milestones. If warrant/guarantee dilution >10% or material milestones absent, move to reduce/close long exposure and increase short size.